Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovoli, Francesco, Negrini, Giulia, Benevento, Francesca, Faggiano, Chiara, Goio, Elisabetta, Granito, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168042/
https://www.ncbi.nlm.nih.gov/pubmed/30302192
http://dx.doi.org/10.2217/hep-2017-0020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168042/
https://www.ncbi.nlm.nih.gov/pubmed/30302192
http://dx.doi.org/10.2217/hep-2017-0020

Ejemplares similares